Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment.
Swan D, Henderson R, McEllistrim C, Naicker SD, Quinn J, Cahill MR, Mykytiv V, Lenihan E, Mulvaney E, Nolan M, Parker I, Natoni A, Lynch K, Ryan AE, Szegezdi E, Krawczyk J, Murphy P, O'Dwyer M. Swan D, et al. Among authors: mykytiv v. Clin Lymphoma Myeloma Leuk. 2022 Nov;22(11):847-852. doi: 10.1016/j.clml.2022.07.011. Epub 2022 Jul 21. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35985959 Clinical Trial.
A multicenter report on the natural history of myelodysplastic syndromes in very old patients (aged over 85 years).
McDonald LS, McCarthy P, Khan M, Hogan P, Kelleher E, Murphy PT, Quinn J, Desmond R, McHugh J, Strickland M, O'Connell E, Cahill M, Maung SW, Keohane C, O'Neill D, Ryan D, Mykytiv V, Enright H. McDonald LS, et al. Among authors: mykytiv v. Leuk Lymphoma. 2019 May;60(5):1324-1327. doi: 10.1080/10428194.2018.1538513. Epub 2019 Jan 11. Leuk Lymphoma. 2019. PMID: 30632846 No abstract available.
CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.
O'Dwyer M, Henderson R, Naicker SD, Cahill MR, Murphy P, Mykytiv V, Quinn J, McEllistrim C, Krawczyk J, Walsh J, Lenihan E, Kenny T, Hernando A, Hirakata G, Parker I, Kinsella E, Gannon G, Natoni A, Lynch K, Ryan AE. O'Dwyer M, et al. Among authors: mykytiv v. Blood Adv. 2019 Jun 25;3(12):1815-1825. doi: 10.1182/bloodadvances.2019000010. Blood Adv. 2019. PMID: 31201169 Free PMC article. Clinical Trial.
Molecular responses in e19a2 BCR-ABL1 chronic myeloid leukemia.
Kearney L, Crampe M, Conneally E, Krawczyk J, Kumar S, Murphy PT, Mykytiv V, Ryan MF, Langabeer SE. Kearney L, et al. Among authors: mykytiv v. Leuk Res Rep. 2020 Mar 12;13:100195. doi: 10.1016/j.lrr.2020.100195. eCollection 2020. Leuk Res Rep. 2020. PMID: 32211287 Free PMC article. No abstract available.
Double CD38-/CD138- negative multiple myeloma.
Mykytiv V, Alwaheed A, Mohd Hashim NA. Mykytiv V, et al. Hematol Oncol Stem Cell Ther. 2019 Mar;12(1):64-66. doi: 10.1016/j.hemonc.2017.08.003. Epub 2017 Oct 18. Hematol Oncol Stem Cell Ther. 2019. PMID: 29079129 Free article.
18 results